Brecken, 12, began receiving Avidity Biosciences’ experimental exon-skipping drug last winter and has steadily improved. The treatment enables production of a shortened but functional protein essential to muscle survival and appeared to nearly halt Duchenne muscular dystrophy in some trial patients,